✦ LIBER ✦

Cost-effectiveness of cognitive-behavioral group therapy for dysfunctional fear of progression in cancer patients

✍ Scribed by C. Sabariego; M. Brach; P. Herschbach; P. Berg; G. Stucki

Publisher: Springer
Year: 2010
Tongue: French
Weight: 401 KB
Volume: 12
Category: Article
ISSN: 1618-7598
DOI: 10.1007/s10198-010-0266-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Evaluation of two group therapies to red

Evaluation of two group therapies to reduce fear of progression in cancer patients

✍ Peter Herschbach; Katrin Book; Andreas Dinkel; Petra Berg; Sabine Waadt; Gabriel 📂 Article 📅 2009 🏛 Springer-Verlag 🌐 English ⚖ 164 KB

Cost effectiveness of individual vs. gro

Cost effectiveness of individual vs. group cognitive behavior therapy for problems of depression and anxiety in an HMO population

✍ Joan Shapiro; Lawrence I. Sank; Carolyn S. Shaffer; Donna Coghlan Donovan 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 334 KB 👁 2 views

Cost-Effectiveness of Recombinant Activa

Cost-Effectiveness of Recombinant Activated Factor VII as Adjunctive Therapy for Bleeding Control in Severely Injured Trauma Patients in Germany

✍ Rolf Rossaint; Michael C. Christensen; Philip Iau Tsau Choong; Kenneth D. Boffar 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 367 KB

A preliminary investigation of the effec

A preliminary investigation of the effects of cognitive behavioral therapy for panic disorder on gastrointestinal distress in patients with comorbid panic disorder and irritable bowel syndrome

✍ Daniel F. Gros; Martin M. Antony; Randi E. McCabe; R. Bruce Lydiard 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB 👁 2 views

Estimating survival gain for economic ev

Estimating survival gain for economic evaluations with survival time as principal endpoint: A cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer

✍ N. Neymark; I. Adriaenssen; T. Gorlia; S. Caleo; M. Bolla 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 240 KB 👁 1 views

## Abstract The problem of estimating expected outcomes for the economic evaluation of treatments for which the outcome of principal interest is (quality adjusted) survival time has so far not received sufficient attention in the literature. The best estimate of expected survival is mean survival t

Cost-effectiveness analysis of anastrozo

Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial

✍ Gershon Y. Locker; Robert Mansel; David Cella; Deborah Dobrez; Sonja Sorensen; S 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 267 KB